News & Events

The Laboratory of Radiochemistry (LRC) and the Centre for Radiopharmaceutical Sciences (CRS) are key partners in the development of the emerging TATTOOS facility, a cornerstone of the IMPACT project recently approved for funding by the Swiss Parliament. TATTOOS will enable the production of essential radionuclides for cutting-edge radiopharmaceuticals, revolutionising cancer diagnostics and treatment. Building on PSI’s expertise and its proton accelerator, this initiative represents a significant advancement in personalised cancer therapy and nuclear medicine. For more information: external page https://www.psi.ch/en/news/media-releases/impact-upgrade-at-psi-research-facility-approved

Dr. Chiara Favaretto has been honoured with the Alavi-Mandell Award from the Journal of Nuclear Medicine (JNM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for her publication “¹⁶¹Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of ¹⁶¹Tb into the Clinic” (Journal of Nuclear Medicine July 2023, 64 (7) 1138-1144; DOI: external page https://doi.org/10.2967/jnumed.122.265268). The award is given to individuals who were the first author of a paper published in the JNM and made a major contribution to the completion of the work.

Established by Dr. Abass Alavi, MD, and Dr. Gerald Mandell, MD, in memory of their fathers, the Alavi-Mandell Award aims to encourage young physicians and scientists to pursue careers in academic and research in nuclear medicine.

We congratulate Dr. Chiara Favaretto for the excellent research work she did during her time at the Center for Radiopharmaceutical Sciences.

The translational project "PROGNOSTICS", proposed by a consortium led by Prof. Roger Schibli, received CHF 2 million funding from the PHRT initiative of the external page ETH Domain. The study is being conducted with the Co-applicants Prof. Dr. med. Damian Wild at the University Hospital Basel and Prof. Dr. Nicola Aceto of the ETHZ. The consortium will test a new radiopharmaceutical developed at the Center for Radiopharmaceutical Sciences in 36 patients with advanced prostate cancer.